AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bausch Health Companies I... (BHC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.18

0.67 (10.29%)

At close: Feb 20, 2025, 3:59 PM

7.18

0.00%

After-hours: Feb 20, 2025, 07:00 PM EST

undefined% (undefined)

Bid	7.01
Market Cap	2.64B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.48
PE Ratio (ttm)	-14.96
Forward PE	n/a
Analyst	Hold

Ask	7.35
Volume	5,674,223
Avg. Volume (20D)	2,433,274
Open	7.02
Previous Close	6.51
Day's Range	6.96 - 7.49
52-Week Range	3.96 - 11.46
Beta	undefined

About BHC

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Mar 29, 1994

Employees 20,270

Stock Exchange NYSE

Ticker Symbol BHC

Website https://www.bauschhealth.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 11.42% from the latest price.

Buy 0.00%

Hold 80.00%

Sell 20.00%

Stock Forecasts

Next Earnings Release

Bausch Health Companies Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

15 hours ago New

Bausch Health shares are trading higher after the ... Unlock content with Pro Subscription

2 weeks ago

-10.9%

Bausch Health shares are trading lower after the company announced it will continue to own its 88% interest in Bausch + Lomb.

News

19 hours ago · seekingalpha.com

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long...

22 hours ago · zacks.com

Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

1 day ago · zacks.com

Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street...

1 day ago · seekingalpha.com

Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conf...

1 day ago · zacks.com

Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago.

1 day ago · accessnewswire.com

Bausch Health Announces Fourth Quarter and Full-Year 2024 Results

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Reve...

1 day ago · businesswire.com

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-qua...

3 days ago · zacks.com

What Analyst Projections for Key Metrics Reveal About Bausch (BHC) Q4 Earnings

Beyond analysts' top -and-bottom-line estimates for Bausch (BHC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e...

6 days ago · accessnewswire.com

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference...

1 week ago · zacks.com

Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News